Navigation Links
Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Spain Pharmaceutical Market Overview – Price cuts set to negatively impact both branded and generics companies – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html

IntroductionThe Spanish prescription pharmaceutical market was valued at $22.1bn in sales in 2009, with an annual growth rate of 6.4% between 2008 and 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by an aging population, with a high proportion of healthcare expenditure spent on prescription pharmaceuticals.

Features and benefits

* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in Spain

* Assesses the size of the Spanish pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

* Examines the Spanish generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

HighlightsFor newly patented drugs, when deciding on the reimbursement price, the CIPM evaluates a number of factors, including the cost of manufacturing and research and development, cost per day compared with equivalent products in Spain, sales forecast, expected impact on the SNS budget and the product's price in other low-cost European countries.

The Introduction of reference pricing in Spain during 2000, numerous rounds of price cuts, the low price differential between brands and generics, and insufficient physician incentives and the lack of requirement to prescribe by International Non proprietary Name has limited generic penetration as well as the profit potential of generics players.

The Spanish government is trying to restore confidence in the Spanish pharmaceutical market and is working on a strategic plan to develop its sector through increased investment and job creation. Nevertheless, this is still in the early stages and details are yet to be announced.

Your key questions answered* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Spain

* Quantify the size and growth of the prescription pharmaceutical market in Spain, analyzing key therapy areas, brands and companies

* Assess drivers and resistors of generic and biosimilars uptake in Spain

To order this report:: Spain Pharmaceutical Market Overview – Price cuts set to negatively impact both branded and generics companies

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion
2. Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
3. Reportlinker Adds The Endoscopy Device Market Outlook to 2015
4. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
5. Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)
6. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
7. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
8. Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth
9. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
10. Reportlinker Adds Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile
11. Reportlinker Adds Cosmetic Surgery Products
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary Hypertension ... and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping ... public, will receive special recognition throughout 2016 as part of PHA’s 25th anniversary ...
(Date:11/25/2015)... ... 25, 2015 , ... Bcureful—a non-profit organization devoted to advancing ... public awareness of the disorder while helping to bring expert medical care and ... bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert H. ...
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... sizes, has launched their Black Friday sale a week early, offering 40% off ... to transform the intimate apparel industry through both mobile fit technology and the ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
Breaking Medicine News(10 mins):